Health Canada approves Xience V
This article was originally published in Clinica
Abbott's everolimus-eluting Xience V stent has gained Canadian approval for the treatment of coronary artery disease (CAD). Abbott will launch the device in Canada immediately on both over-the-wire and rapid exchange delivery systems. Cardiovascular disease is the leading cause of death in Canada, and 54% of all cardiovascular deaths are due to CAD.